Prof. Van Buyten is currently the Chairman of the Multidisciplinary Pain Management Center in AZ Nikolaas Hospital in Sint-Niklaas Belgium and Consultant in Pain Medicine in Delta Hospital (member of the Chirec group) Brussels Belgium. He is a founding member of the BENELUX Chapter of International Neuromodulation Society, chairman of the executive board of the European Continuing Medical Training, a non-profit organization which organizes more than 40 meetings and workshops per year for education in the field of neuromodulation in EU. He is also a member of the Belgian Pain Society, and founding member, Past President and currently member of the board of VAVP (Vlaamse Anesthesiologische Vereniging voor Pijnbestrijding). He is an active researcher in the field of neuromodulation and pain management for many years and has published number of scientific publications. He served in many advisory boards of Medical device companies. Dr. JP Van Buyten is lecturing on Pain Management in most of the international congress’s all over the globe.

Prof. Paemeleire is a neurologist at the Department of Neurology of the Ghent University Hospital in Belgium and runs a specialized headache clinic since 2004. He was also appointed part-time Senior Lecturer in Neurophysiology at the Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Belgium. His research focuses on the management of headache (including digital health applications most recently), neuromodulation techniques and migraine neurobiology. He is associate editor of the Journal of Headache and Pain.

Prof. Schoenen is a neurologist, founding director of the Headache Research Unit at the neurology department and Honorary full professor at Liège University. He trained at the Neurology and Neuropathology Departments of the Massachusetts General Hospital and at the Neuroanatomy Department of Harvard Medical School. He is board-certified neurologist since 1979 and holds doctoral and post-doctoral degrees from Liège University. He was Research Director of the National Fund for Scientific Research-Belgium and Clinical Professor in Neurology. He is former chairman of the Department of Biomedical and Preclinical Sciences at the Faculty of Medicine – ULg. His Research has focused on headaches and spinal cord anatomy and pathology. He was Associate Editor of Cephalalgia and Editor-in-Chief of Acta Neurologica Belgica. He is Founder of the Belgian Brain Council and a former President of the International Headache Society, the European Headache Federation and the Belgian Neurological Society. He published 483 peer-reviewed articles (H index: 92; i10 index: 348; 33,837 citations), 4 books, 98 book chapters and holds 1 patent.

Mr. Suarez joined Man & Science  as chief executive officer as of January 2022. He served as Chief Financial Officer from 2014 to 2021 at Nyxoah, a neurostimulation medtech company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea. Fabian oversaw the finance department and was responsible for infrastructure, IT, human resources and payroll, and other administrative operations. He was instrumental in the preparation and completion of Nyxoah’s IPOs on Euronext (September 2020) and Nasdaq (July 2021). From 2005 to 2014, he held senior roles in several private equity firms, mainly in the renewable energy sector.   

Mr. Suarez holds a double MSc. in Physics and Actuarial Sciences from Université Libre de Bruxelles and an MBA from Solvay Brussels School of Economics and Management. 

Hervé Mével joined the company in 2021 as VP product development & QARA. He has a long-standing expertise in the development of medical device Class II-III from concept to product launch, having worked in the implantable medical device field for more than 20 years. After graduating with a degree in electronic engineering, Hervé worked in Belgium, France and the USA in various functions including leadership roles for NeuroTech (Epilepsy treatment VNS, sleep apnea, DBS), the Sorin Group ( heart failure treatment by neuromodulation), Cairdac (leadless pacemaker), Metronom Health (diabetes treatment) and MELLIsim (diabetes treatment).

Christelle joined the company in 2019 as Project Manager and Clinical Research Coordinator. She has over 15 years of experience in the nursing field in Europe and the United States. Prior to Man & Science she worked as Clinical Study Coordinator and Study Nurse at UHC Saint-Pierre Brussels covering multiple Phase II- IV trials. She has wide experience in the management of clinical trial projects from initiation to close out as well as working with site investigators to improve patient recruitment and patient retention. In addition to her nursing degrees, Christelle holds a Master’s degree in Science of Public Health from the Université Libre de Bruxelles.

Véronique joined Man & Science in 2020 as financial & administrative manager. Prior to Man & Science, she spent 7 years as Investment Manager at Fortino Capital (Venture and Growth Capital) and E-Capital (Private Equity) in Brussels, responsible for the full investment cycle from deal sourcing to exit. Prior to these positions, she was an M&A advisor (financial due diligence) at PricewaterhouseCoopers Belgium. Véronique received her Master’s degree in business engineering at Solvay Brussels School.

Mireya joined the company in October 2021 as Quality Assurance Manager. In addition to a Master in chemical engineering from Ecole Polytechnique de Montréal, she obtained a PhD degree in material science and nanocomposites from Institut des Sciences Appliquées de Lyon. Mireya has a large experience in the area of polymers and biomaterials. For the last 12 years, she worked in the medical device industry (class II and III implantable devices), as R&D Project Manager for Cardiatis, from initial device design to the final commercial phase, and as Quality Manager for Brussels Medical Device Center (BMDC). She also holds a training certificate in clinical, regulatory and quality affairs from the Université Catholique de Louvain.